insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2026 Vol.219() p. 111519

Miller DG, Zhang YH, Thor M, Shin JY, Imber BS, Offin MD, Haseltine J, Chaunzwa TL, Wu AJ, Billing DL, Ma J, McMillan MT, Simone CB, Gelblum DY, Yamada Y, Iyengar P, Chaft JE, Gomez DR, Shaverdian N

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

We evaluated acute toxicity and disease control in 42 patients receiving thoracic radiotherapy with concurrent KRAS G12C inhibitors.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Miller DG, Zhang YH, et al. (2026). Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 219, 111519. https://doi.org/10.1016/j.radonc.2026.111519
MLA Miller DG, et al.. "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol. 219, 2026, pp. 111519.
PMID 41933595
DOI 10.1016/j.radonc.2026.111519

Abstract

We evaluated acute toxicity and disease control in 42 patients receiving thoracic radiotherapy with concurrent KRAS G12C inhibitors. Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis. There were no significant differences in toxicity between patients who held versus continued inhibitors during radiotherapy. The estimated cumulative incidence of local failure at 6 months was 5%.

같은 제1저자의 인용 많은 논문 (1)